Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Oral Semaglutide

Stage Phase 3Stale

Sponsor Novo Nordisk A/S

Route oral

Class GLP-1 RA

Mechanism GLP-1 receptor agonist

Sources

fda, as of 2026-05-05Stale

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/215256Orig1s031.pdf

Sponsor: Novo Nordisk Inc. Trade Name: WEGOVY. Generic or Proper Name: semaglutide. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity. WEGOVY tablets are indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity.

Approval package 215256Orig1s031, highlights and Table 8 Study 2 and Table 12 Study 8

registry, as of 2026-05-07Stale

https://clinicaltrials.gov/study/NCT05035095

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1). Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 667. Conditions Obesity; Overweight. This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or Percentage Change in Body Weight Oral Semaglutide 50 mg -15.8 Percentage (%) change in body weight Baseline (week 0), end-of-treatment (week 68) Percentage Change in Body Weight Placebo -2.2 Percentage (%) change in body weight Baseline (week 0), end-of-treatment (week 68) Change in Glycosylated Haemoglobin (HbA1c) Oral Semaglutide 50 mg -0.2 Percentage

ClinicalTrials.gov NCT05035095 protocol and results modules

registry, as of 2026-09-09Stale

https://clinicaltrials.gov/study/NCT07770841

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 450. Conditions Overweight; Obesity. The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semagl

ClinicalTrials.gov NCT07770841 protocol and results modules

registry, as of 2026-02-25Stale

https://clinicaltrials.gov/study/NCT05564117

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 307. Conditions Overweight; Obesity. This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screenin Percentage Change in Body Weight Oral Semaglutide 25 mg -14.4 Percentage change in body weight Baseline (week 0), end of treatment (week 64) Percentage Change in Body Weight Placebo -2.5 Percentage change in body weight Baseline (week 0), end of treatment (week 64) Change in Glycosylated Haemoglobin (HbA1c) Oral Semaglutide 25 mg -0.3 Percentage of HbA1c Change

ClinicalTrials.gov NCT05564117 protocol and results modules

registry, as of 2026-08-14Stale

https://clinicaltrials.gov/study/NCT05132088

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 201. Conditions Overweight and Obesity. Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight. Participants will either get semaglutide tablets (new medicin Percent Change From Baseline in Body Weight Oral Semaglutide 50 mg -14.9 Percent change of body weight Baseline (week 0), week 68 Percent Change From Baseline in Body Weight Oral Semaglutide Placebo -1.5 Percent change of body weight Baseline (week 0), week 68 Change From Baseline in Glycosylated Haemoglobin (HbA1c) Oral Semaglutide 50 mg -0.8 Change

ClinicalTrials.gov NCT05132088 protocol and results modules

registry, as of 2026-01-22Stale

https://clinicaltrials.gov/study/NCT05890976

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3). Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 200. Conditions Overweight; Obesity. This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either

ClinicalTrials.gov NCT05890976 protocol and results modules

Studies

OASIS 1

Registry NCT05035095

EudraCT 2020-002953-11

Phase Phase 3

Status Completed

Enrollment 667

Start 2021-09-13

Primary completion 2023-03-24

Study completion 2023-05-12

Oral semaglutide

Regimen once daily

Weeks 1

Comparator placebo

Population Obesity; Overweight

percent change in body weight, -15.8 %Stale

change in HbA1c, -0.2 Percentage of HbA1cStale

deaths

participants with diarrhoea, 89 participantsStale

participants with nausea, 173 participantsStale

participants with vomiting, 80 participantsStale

Oral semaglutide placebo

Regimen once daily

Weeks 1

Population Obesity; Overweight

percent change in body weight, -2.2 %Stale

change in HbA1c, 0.1 Percentage of HbA1cStale

deaths

participants with diarrhoea, 56 participantsStale

participants with nausea, 51 participantsStale

participants with vomiting, 12 participantsStale

OASIS 5

Registry NCT07770841

Phase Phase 3

Status Recruiting

Enrollment 450

Start 2026-08-12

Primary completion 2028-02-22

Study completion 2028-04-11

Catalyst Primary completion. 2028-02-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide

Regimen once daily

Comparator placebo

Population Overweight; Obesity

Placebo

Regimen once daily

Population Overweight; Obesity

OASIS 4

Registry NCT05564117

EudraCT 2021-006534-40

Phase Phase 3

Status Completed

Enrollment 307

Start 2022-10-11

Primary completion 2024-04-18

Study completion 2024-05-07

Oral semaglutide 25 mg

Dose 25 mg

Regimen once daily

Comparator placebo

Population Overweight; Obesity

percent change in body weight, -14.4 %Stale

change in HbA1c, -0.3 Percentage of HbA1cStale

deaths

participants with diarrhoea, 36 participantsStale

participants with nausea, 95 participantsStale

participants with vomiting, 63 participantsStale

Oral semaglutide placebo

Regimen once daily

Population Overweight; Obesity

percent change in body weight, -2.5 %Stale

change in HbA1c, 0 Percentage of HbA1cStale

deaths

participants with diarrhoea, 9 participantsStale

participants with nausea, 19 participantsStale

participants with vomiting, 6 participantsStale

OASIS 2

Registry NCT05132088

Phase Phase 3

Status Completed

Enrollment 201

Start 2021-11-16

Primary completion 2023-07-11

Study completion 2023-09-01

oral semaglutide 50 mg once daily

Dose 50 mg

Regimen once daily

Weeks 68

Comparator placebo

Population Overweight and Obesity

Estimand ITT

percent change in body weight, -14.9 %Stale

change in HbA1c, -0.8 Change in HbA1c (%)Stale

deaths

participants with diarrhoea, 22 participantsStale

participants with nausea, 34 participantsStale

participants with vomiting, 20 participantsStale

oral semaglutide placebo once daily

Regimen once daily

Weeks 68

Population Overweight and Obesity

Estimand ITT

percent change in body weight, -1.5 %Stale

change in HbA1c, 0 Change in HbA1c (%)Stale

deaths

participants with diarrhoea, 6 participantsStale

participants with nausea, 5 participantsStale

participants with vomiting, 2 participantsStale

OASIS 3

Registry NCT05890976

Phase Phase 3

Status Completed

Enrollment 200

Start 2023-05-30

Primary completion 2025-01-16

Study completion 2025-01-16

Catalyst Primary completion. 2025-01-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide 50 mg

Dose 50 mg

Regimen once daily

Comparator placebo

Population Overweight; Obesity

Semaglutide Placebo

Regimen once daily

Population Overweight; Obesity